171 related articles for article (PubMed ID: 15578103)
21. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.
Migita M; Hamada H; Fujimura J; Watanabe A; Shimada T; Fukunaga Y
Eur J Pediatr; 2003 Jul; 162(7-8):524-525. PubMed ID: 12845529
[No Abstract] [Full Text] [Related]
22. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
23. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
24. Gaucher disease: hematologic and oncologic implications.
Hughes D
Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
[No Abstract] [Full Text] [Related]
25. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.
Schiffmann R; Mankin H; Dambrosia JM; Xavier RJ; Kreps C; Hill SC; Barton NW; Rosenthal DI
Blood Cells Mol Dis; 2002; 28(2):288-96. PubMed ID: 12064924
[TBL] [Abstract][Full Text] [Related]
26. Enzyme Replacement Therapy in a Gaucher Family.
Erdem N; Buran T; Berber I; Aydogdu I
J Natl Med Assoc; 2018 Aug; 110(4):330-333. PubMed ID: 30126557
[TBL] [Abstract][Full Text] [Related]
27. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.
Hollak CE; de Fost M; van Dussen L; Vom Dahl S; Aerts JM
Expert Opin Pharmacother; 2009 Nov; 10(16):2641-52. PubMed ID: 19743939
[TBL] [Abstract][Full Text] [Related]
28. Low-dose versus high-dose therapy for Gaucher disease: Goals and markers.
Hollak CE; de Fost M; Aerts JM; vom Dahl S
Blood; 2007 Jan; 109(1):387; author reply 387-8. PubMed ID: 17190857
[No Abstract] [Full Text] [Related]
29. Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.
van Breemen MJ; de Fost M; Maas M; Wiersma MG; Hollak CE; Poll LW; Vom Dahl S; Boot RG; Aerts JM
J Inherit Metab Dis; 2009 Apr; 32(2):274-9. PubMed ID: 19255873
[TBL] [Abstract][Full Text] [Related]
30. Alglucerase (Ceredase).
Wiltink EH; Hollak CE
Pharm World Sci; 1996 Jan; 18(1):16-9. PubMed ID: 8861826
[No Abstract] [Full Text] [Related]
31. Imiglucerase treatment in Gaucher's disease.
Shah U; Nadeem N; Husen Y; Fadoo Z
J Ayub Med Coll Abbottabad; 2007; 19(2):56-9. PubMed ID: 18183722
[TBL] [Abstract][Full Text] [Related]
32. Enzyme-replacement therapy for Gaucher's disease.
N Engl J Med; 1991 Dec; 325(25):1809-11. PubMed ID: 1944489
[No Abstract] [Full Text] [Related]
33. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
[TBL] [Abstract][Full Text] [Related]
34. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
Elstein D; Abrahamov A; Altarescu G; Zimran A
Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
[No Abstract] [Full Text] [Related]
35. Uveitis in Gaucher disease.
Dweck A; Rozenman J; Ronen S; Zimran A; Elstein D
Am J Ophthalmol; 2005 Jul; 140(1):146-7. PubMed ID: 16038664
[TBL] [Abstract][Full Text] [Related]
36. Enzyme therapy for Gaucher disease: the first 5 years.
Grabowski GA; Leslie N; Wenstrup R
Blood Rev; 1998 Jun; 12(2):115-33. PubMed ID: 9661800
[TBL] [Abstract][Full Text] [Related]
37. Short-term withdrawal from imiglucerase: what can we learn from it?
Hollak CE
Blood Cells Mol Dis; 2011 Jan; 46(1):105-6. PubMed ID: 20684887
[No Abstract] [Full Text] [Related]
38. EVALUATION OF EFFICIENCY OF IMIGLUCERASE (CEREZYME) IN THE TREATMENT OF GAUCHER DISEASE (CASE REPORTS AND REVIEW OF THE LITERATURE).
Samohalska O; Kornaga S; Mandziy Z; Boiko T; Radetska L
Georgian Med News; 2018 Feb; (Issue):69-73. PubMed ID: 29578427
[TBL] [Abstract][Full Text] [Related]
39. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.
Czartoryska B; Tylki-Szymańska A; Lugowska A
Clin Biochem; 2000 Mar; 33(2):147-9. PubMed ID: 10751594
[No Abstract] [Full Text] [Related]
40. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease.
Campbell PE; Harris CM; Vellodi A
Neurology; 2004 Jul; 63(2):385-7. PubMed ID: 15277647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
